Marrone Bio Innovations Inc (NASDAQ:MBII) Expected to Post Quarterly Sales of $9.01 Million

Wall Street analysts expect Marrone Bio Innovations Inc (NASDAQ:MBII) to report $9.01 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Marrone Bio Innovations’ earnings. The lowest sales estimate is $7.92 million and the highest is $10.10 million. Marrone Bio Innovations reported sales of $5.75 million during the same quarter last year, which indicates a positive year-over-year growth rate of 56.7%. The firm is expected to issue its next earnings results on Tuesday, August 13th.

According to Zacks, analysts expect that Marrone Bio Innovations will report full year sales of $31.66 million for the current year, with estimates ranging from $27.00 million to $36.52 million. For the next financial year, analysts anticipate that the company will report sales of $40.70 million, with estimates ranging from $34.00 million to $46.77 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Marrone Bio Innovations.

Marrone Bio Innovations (NASDAQ:MBII) last posted its quarterly earnings data on Thursday, May 9th. The basic materials company reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04). Marrone Bio Innovations had a negative return on equity of 123.95% and a negative net margin of 82.82%. The company had revenue of $8.72 million during the quarter, compared to analysts’ expectations of $6.18 million.

Separately, National Securities reissued a “buy” rating and issued a $2.50 price target on shares of Marrone Bio Innovations in a report on Friday, March 15th.

Marrone Bio Innovations stock traded up $0.03 during mid-day trading on Friday, reaching $1.43. 65,029 shares of the company were exchanged, compared to its average volume of 124,295. Marrone Bio Innovations has a twelve month low of $1.10 and a twelve month high of $2.18. The stock has a 50-day moving average price of $1.58. The company has a current ratio of 1.94, a quick ratio of 1.47 and a debt-to-equity ratio of 2.47. The stock has a market capitalization of $158.34 million, a price-to-earnings ratio of -6.81 and a beta of -0.05.

Institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. lifted its holdings in shares of Marrone Bio Innovations by 0.5% in the 4th quarter. BlackRock Inc. now owns 2,800,519 shares of the basic materials company’s stock valued at $4,117,000 after buying an additional 14,014 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Marrone Bio Innovations by 13.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,554,605 shares of the basic materials company’s stock valued at $4,675,000 after buying an additional 303,201 shares during the period. Spark Investment Management LLC lifted its holdings in shares of Marrone Bio Innovations by 47.5% in the 1st quarter. Spark Investment Management LLC now owns 95,000 shares of the basic materials company’s stock valued at $145,000 after buying an additional 30,600 shares during the period. Rhumbline Advisers lifted its holdings in shares of Marrone Bio Innovations by 44.3% in the 4th quarter. Rhumbline Advisers now owns 68,021 shares of the basic materials company’s stock valued at $100,000 after buying an additional 20,882 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Marrone Bio Innovations in the 1st quarter valued at approximately $74,000. 42.04% of the stock is owned by institutional investors and hedge funds.

About Marrone Bio Innovations

Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.

Featured Article: Risk Tolerance

Get a free copy of the Zacks research report on Marrone Bio Innovations (MBII)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Marrone Bio Innovations (NASDAQ:MBII)

Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.